Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Royalty Pharma (NASDAQ:RPRX) released its earnings results on Tuesday. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16, Zacks reports. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%.

Royalty Pharma Trading Up 1.7 %

Shares of Royalty Pharma stock opened at $32.25 on Wednesday. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $32.72. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a 50 day moving average price of $27.93 and a two-hundred day moving average price of $27.65. The stock has a market capitalization of $19.00 billion, a PE ratio of 16.71 and a beta of 0.49.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Analyst Ratings Changes

Several research firms recently commented on RPRX. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.